|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/506 | (2006.01) |
| A61P 25/28 | (2006.01) |
| (11) | Number of the document | 4125911 |
| (13) | Kind of document | T |
| (96) | European patent application number | 22715162.8 |
| Date of filing the European patent application | 2022-03-04 | |
| (97) | Date of publication of the European application | 2023-02-08 |
| (45) | Date of publication and mention of the grant of the patent | 2024-04-24 |
| (46) | Date of publication of the claims translation | 2024-08-12 |
| (86) | Number | PCT/IB2022/000098 |
| Date | 2022-03-04 |
| (87) | Number | WO 2022/185120 |
| Date | 2022-09-09 |
| (30) | Number | Date | Country code |
| 202163157586 P | 2021-03-05 | US |
| (72) |
DITMARSCH, Marc , NL
KASTELEIN, Johannes Jacob Pieter , NL
DAVIDSON, Michael Harvey , NL
|
| (73) |
NewAmsterdam Pharma B.V. ,
(dutch Chamber of Commerce No. 55971946)
Gooimeer 2-35, 1411 DC Naarden,
NL
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Obicetrapibas demencijų gydymui |
| OBICETRAPIB FOR TREATMENT OF DEMENTIAS |
| Payment date | Validity (years) | Amount | |
| 2025-02-14 | 4 | 92.00 EUR |
| 2026-03-04 |